Since this study was published in 2012, MMAE-linked anti-ANTXR1 antibody drug conjugate (ADC) treatments have been developed and shown to be well tolerated and capable of inducing tumor regression or tumor eradication in multiple solid tumor types, inhibiting metastatic growth and prolonging overall in vivo survival [45]. This evidence concerns the gene ANTXR1 and neoplasm.